Filgrastim during combination chemotherapy of patients with poor- prognosis metastatic germ cell malignancy

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 716-724

  Fosså, Sophie D ^a   Kaye, Stan B ^a   Mead, Graham M ^a   Cullen, Michael ^a   De Wit, Ronald ^a   Bodrogi, Istvan ^a   Van Groeningen, Cees J ^a   De Mulder, Pieter H M ^a   Stenning, Sally ^a   Lallemand, Eric ^a   De Prijck, Linda ^a   Collette, Laurence ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEVER; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031943040     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.716     Document Type: Article

References (30)

1. Champlin RE, Nimer SD, Ireland P, et al: Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 73:694-699, 1989
2. Jakubowski A, Souza LM, Fain K, et al: Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 320:38-42, 1989
3. Gerhartz HH, Engelhard M, Meusers P, et al. Randomized double-blind, placebo-controlled Phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 82:2329-2339, 1993
4. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
5. Bregni M, Siena S, Di Nicola M, et al: Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 14:628-635, 1996
6. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer (r-metHUG-CSF). N Engl J Med 325:164-170, 1991
7. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
8. Pettengell R, Gurney J, Manegold C, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
9. Neidhart JA: Dose-intensity treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Breast Cancer Res Treat 20:S15-S23, 1991
10. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, et al: Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level. J Clin Oncol 10:1266-1277, 1992
11. Einhorn L: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1877-1881, 1990
12. Lewis CR, Fosså SD, Mead G, et al: A new platinum-intensive chemotherapy regimen for poor prognosis germ cell rumours. Ann Oncol 2:203-211, 1991
13. Mead GM, Stenning SP, Parkinson MC, et al: The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 10:85-94, 1992
14. Kaye et al, in press
15. International Germ Cell Cancer Collaborative Group (IGCCCG). The International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastastic germ cell cancers. J Clin Oncol 15:594-603, 1997
16. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
17. Loehrer PJ Sr, Elson P, Dreicer R, et al: Escalated dosages of methotrexate, vinblasline, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 12:483-488, 1994
18. Mayordomo JI, Rivera F, Diaz-Puente MT, et al: Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: Results of a randomized trial. Proc Amer Soc Clin Oncol 12:437, 1993 (abstr)
19. Riikonen P, Saarinen UM, Makipemaa A, et al: rh GM-CSF in the treatment of fever and neutropenia: A double-blind placebo-controlled study in children with malignancy. Proc Amer Soc Clin Oncol 12:442, 1993 (abstr)
20. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose-intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group Protocol. J Clin Oncol 9:1163-1172, 1991
21. Bokemeyer C, Harstrick A, Metzner B, et al: for the German Testicular Cancer Study Group: Sequential high-dose VIP-chemotherapy plus peripheral stem cell support for advanced germ cell cancer. Ann Oncol 7:2590, 1996
22. Horwich A, Sleijfer DT, Fosså SD, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 12:1844-1852, 1997
23. de Wit R, Stoter G, Sleijfer DT, et al: Four cycles of BEP versus an alternating of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71:1311-1314, 1995
24. Loehrer PJ, Einhorn LH, Elson P, et al: Phase III study of cisplatin (P) plus etoposide (VP16) with either bleomycin (B) or ifosfamide (I) in advanced stage germ cell tumors (GCT): An intergroup trial. Proc Am Soc Clin Oncol 12:261, 1993 (abstr)
25. 16B) or etoposide, ifosfamide and cisplatin (VIP) in advanced stage germ cell tumors; An intergroup trial. Proc Am Soc Clin Oncol 14:239, 1995 (abstr)
26. Stoter G, Sleijfer DTh, Schornagel JH, et al: BEP versus VIP in intermediate risk patients with disseminated non-seminomatous testicular cancer (NSTC). Proc Am Soc Clin Oncol 12:233, 1993 (abstr)
27. Bajorin DF, Nichols CR, Schmoll HJ, et al: Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: A randomized trial. J Clin Oncol 12:79-86, 1995
28. Blanke C, Loehrer P, Einhorn LH, et al: A phase II study of VP-16 plus ifosfamide plus cisplatin plus vinblastine plus bleomycin (VIP/VB) with filgrastim for advanced stage testicular cancer. Proc Am Soc Clin Oncol 13:234, 1994 (abstr)
29. Dirix LY, Schrijvers D, Druwe P, et al: Pulmonary toxicity and bleomycin. Lancet 344:56, 1994
30. Fosså SD, Poulsson JP, Aaserud A: Alkaline phosphatase and lactate dehydrogenase changes during leucocytosis-induced G-CSF in testicular cancer. Lancet 340:1544, 1993; (letter)